Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review
- 24 August 2012
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 136 (2) , 323-330
Abstract
The purpose of this study is to provide more definite evidence regarding the role of dose modification of chemotherapy in obese women with breast cancer by systematically reviewing current literature regarding chemotherapy-induced toxicity rates in obese and non-obese women with early-stage breast cancer. A systematic search of Pubmed and EMBASE was conducted to identify original studies investigating chemotherapy-induced toxicity in obese women receiving adjuvant chemotherapy treatment for breast cancer. Ten studies were identified. We noted low rates of adjustment for confounders such as prophylactic hematopoietic growth factor use and empirical dose reductions. Seven studies found reduced toxicity in obese compared to non-obese women. Of four studies, where dose capping was precluded or statistically adjusted for, three found reduced toxicity in obese women. These outcomes include less febrile neutropenia (body mass index (BMI) >23.6; odds ratio (OR) 4.4; 95 % confidence interval (CI) 1.65–12.01), fewer hospital admissions (BMI >35; OR 0.61, 95 % CI 0.38–0.97), and fewer neutropenic events (BMI >25; OR 0.49; 95 % CI 0.37–0.66). Only a single study reported higher rates of toxicity in obese women, but this study had significant methodological issues. As a conclusion, we observed that obese patients tolerate chemotherapy better than lean patients. However, this may be confounded by poorly specified dose capping practices and the use of hematopoietic growth factors. Further research should focus on improved documentation of body size, of dose, and of use of growth factors, and analysis of how these affect recurrence rates, toxicity, and survival.Keywords
This publication has 41 references indexed in Scilit:
- Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body massEuropean Journal of Pharmaceutical Sciences, 2010
- Effect of obesity on survival of women with breast cancer: systematic review and meta-analysisBreast Cancer Research and Treatment, 2010
- Description of Current Practices of Empiric Chemotherapy Dose Adjustment in Obese Adult PatientsJournal of Oncology Practice, 2010
- Effect of Obesity on the Pharmacokinetics of Drugs in HumansClinical Pharmacokinetics, 2010
- Dosing chemotherapy in obese patients: Actual versus assigned body surface area (BSA)Cancer Treatment Reviews, 2009
- Chemotherapy Dosing Strategies in the Obese, Elderly, and Thin Patient: Results of a Nationwide SurveyJournal of Oncology Practice, 2008
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesThe Lancet, 2008
- Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the ObeseJournal of Clinical Oncology, 2007
- Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy ToxicityClinical Cancer Research, 2007
- Relationships between body composition parameters and fluorouracil pharmacokineticsBritish Journal of Clinical Pharmacology, 2002